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Type 2 diabetes mellitus is a serious, chronic, progressive and widespread disease. Metformin is the most
commonly prescribed initial therapy, but combination with other antidiabetic agents usually becomes necessary
due to the progression of the disease. Pioglitazone is recommended as a second-line therapy because of its strong
antihyperglycemic effect and its ability to reduce insulin resistance. Treatment with pioglitazone is associated with a
significantly lower risk of cardiovascular complications and hypoglycemia, while simultaneously improving the lipid
profile and the symptomatic and histological changes in the liver. Gliptins (sitagliptin and vildagliptin) are a new
class of oral antidiabetic drugs which reduce glycated hemoglobin by a different mechanism. Although the efficacy
of sitagliptin and vildagliptin is close to that of pioglitazone, the lack of long-term safety data and the higher price
question their predominant use. The objective of this review is to highlight the advantages of mono- and
combination therapy with pioglitazone in comparison with gliptins and to underline the inconsistencies in the
medicinal and reimbursement policy in Bulgaria.
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Type 2 diabetes mellitus (T2DM) is a global epidemic with
an estimated worldwide prevalence of 246 million people
(6 %) in 2007 and the number is expected to reach 380 mil-
lion (7.3 %) by 2025 [1]. As a chronic disease with serious
consequences, T2DM requires costly therapy and care.
Metformin is the most commonly prescribed first-line ther-
apy in the world, but due to progressive deterioration of
blood glucose control during the natural progression of the
disease, combination therapy usually becomes a necessity.
Thiazolidinediones (TZDs), such as pioglitazone, are a
class of antidiabetic drugs that exert their action by binding
to peroxisome proliferator-activated receptor gamma
(PPAR-γ) [2]. Peroxisome proliferator-activated receptors
(PPARs) are expressed in various tissues: kidney, heart,
muscle, adipose tissue (PPAR-α); heart, muscle, colon,* Correspondence: e.filipova.hq@tchaikapharma.com
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(PPAR-γ); brain, adipose tissue and skin (PPAR-δ) [3]. The
primary role of PPAR-γ appears to be in regulating glucose
and lipid metabolism along with adipogenesis. PPAR-γ is
thought to enhance the actions of insulin [4]. TZDs bind
specifically with PPAR-γ and by activating these receptors
they perform a variety of biological functions such as the
reduction of insulin resistance, which is responsible for
their application as anti-hyperglycaemic agents. Gliptins are
a new oral drug class for the treatment of T2DM which re-
duce blood sugar (glucose) levels by a different mechanism.
They inhibit the enzyme dipeptidyl peptidase-4 (DPP-4),
thereby increasing the circulating levels of incretins (gut
hormones that enhance insulin secretion). Sitagliptin and
vildagliptin belong to this drug class.
According to the therapeutic guidelines of the National
Institute for Health and Care Excellence (NICE) glitazones
are recommended as second-line therapy in patients
who fail to achieve adequate glycemic control (glycated
hemoglobin (HbA1c) ≥ 6.5 %) after administration ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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has marked insulin sensitivity [5]. Gliptins are also recom-
mended as a second line of therapy, and may be preferable
to TZDs in case of problems with weight gain or if the
TZD (pioglitazone) is contraindicated [5].
The American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD),
in their updated guideline (2015), suggest TZDs and
gliptins as second-line therapy strategies if metformin is
not sufficient for achieving a satisfying HbA1c level [6].
Other strategies offered by both guidelines include
glucagon-like peptide-1 receptor agonists, sodium glu-
cose co transporter-2 inhibitors, sulphonylureas, insu-
lin [5, 6].
Gliptins (sitagliptin, vildagliptin) in combination with
metformin are predominantly used in therapeutic practice
in Bulgaria. Sales of sitagliptin/metformin for 2014 in the
country amounted to BGN 13 million (EUR 6,646,794), and
of vildaglliptin/metfomin – to BGN 12.5 million (EUR
6,391,149) according to IMS (Intercontinental Marketing
Services) Health. Sales of pioglitazone were BGN 0.1 mil-
lion (EUR 51,129).
The established disproportion in sales is due to the differ-
ent levels of reimbursement of medicinal products - sita-
gliptin - 100 %, vildagliptin - 100 %, pioglitazone - 25 %,
sitagliptin/metformin - 50 %, vildaglliptin/metfomin - 50 %.
Decisions for the inclusion of drugs in the Positive Drug
List (PDL) and determination of the levels of reimburse-
ment are made by the National Council on Prices and Re-
imbursement of Medicinal Products (NCPRMP).
This is a comparative analysis of the efficacy, safety and
costs of oral antidiabetic therapies based on gliptins andTable 1 Comparative table of clinical trials investigating the efficacy
Reference N Treatment Baseline values
HbA1c [%]
Lü et al., 2011 [8] 236 SU + PLB In the range of
SU + PIO 30 mg
Scherbaum et al., 2002 [9] 84 PLB + diet
89 PIO 15 mg + diet
78 PIO 30 mg + diet
Yang et al., 2012 [10] 395 MET + PLB 8.5
MET + SIT
Barzilai et al., 2011 [11] 206 PLB 7.8
SIT 50 (100) mg
Yang et al., 2015 [12] 136 SU + PLB 8.6
143 SU + VIL 100 mg 8.7
Lukashevich et al., 2014 [15] 160 PLB + MET + glimepiride 8.80
158 VIL + MET + glimepiride 8.75
EQW exenatide, MET metformin, PIO pioglitazone, SIT sitagliptin, VIL vildagliptin, SU
non-significantglitazones, aiming to assess the objectivity of the decisions
concerning pricing and reimbursement based on pharma-
coeconomic evidence presented by the pharmaceutical
industry.
A search of PubMed, Medline, Sciencedirect, Food
and Drug Administration (FDA), European Medicines
Agency (ЕМА), NCPRMP websites was performed with
the following keywords: TZDs, pioglitazone, DPP-4
inhibitors, gliptins, sitagliptin, vildagliptin, metformin,
efficacy, safety, adverse reactions, and combination
therapy. Original articles and reviews as well as abstracts
discussing the efficacy and safety of pioglitazone,
sitagliptin and vildagliptin mono- or combination therapy,




TZDs favorably influence upon the majority of the com-
ponents of insulin resistance characteristic of T2DM,
like adiposity, dyslipidaemia, hyperglycaemia, hyperten-
sion, cardiovascular abnormalities, hyper coagulation,
vasculopathy, accelerated atherosclerosis, and changes in
liver and ovaries [7]. TZDs, pioglitazone in particular,
successfully reduce HbA1c (Table 1). Studies have shown
decrease in HbA1c of 0.92 % and 1.05 % compared to
placebo for pioglitazone 15 mg and 30 mg, respectively
[8, 9] and some authors even report values of 2 % [4].
When this parameter is considered, the hypoglycemic pro-
file of pioglitazone resembles that of sulphonylurea and
metformin unlike the gliptins for which some authors in-






7.0 to 12.0 −0.28 ± 0.11 +0.17 ± 1.92 SS





−0.9 −1.2 p < 0.001
SS
−0.7 −1.5 p < 0.001
−0.2 SS
−0.7 p < 0.001
−0.25 +0.02 SS
−1.01 −1.11 p < 0.001
sulphonylurea, PLB placebo, SS statistically singnificant, SN statistically
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in comparison with placebo. Other authors claim that sita-
gliptin and vildagliptin provide similar improvements in
HbA1c levels when compared with metformin, sulfonyl-
ureas or glitazones without contributing to weight gain
and hypoglycemia [13] with reductions of HbA1c of up
to−1.0 % for sitagliptin and 0.9 % for vildagliptin [14].
It appears that TZDs reduce fasting plasma glucose
(FPG) as well. Lü et al. have shown that pioglitazone is
more effective in decreasing FPG when compared to pla-
cebo - - 1.48 mmol/L versus control group [8]. The re-
duction in comparison with placebo was 1.2 mmol/L
[10] for sitagliptin and 1.11 mmol/L [15] for vildagliptin,
respectively.
Results from trials conducted on both humans and ani-
mals have shown that TZDs preserve β-cell function, in-
crease high-density lipoprotein (HDL) cholesterol and
low-density lipoprotein (LDL) cholesterol with 10 to 15 %
[16] and decrease triglyceride levels with the latter effect
being more pronounced in the case of pioglitazone [4].
Some studies suggested that gliptins improve lipid param-
eters as well, with vildagliptin having a more beneficial ef-
fect on the lipid profile than sitagliptin [17].Efficacy of monotherapy with pioglitazone compared to
monotherapy with sitagliptin and vildagliptin
The clinical trial DURATION-4 [18], which enrolled 820
subjects (696 completed all 26 weeks of therapy) aimed to
monitor and assess the effectiveness of exenatide, metfor-
min, pioglitazone and sitagliptin in patients with T2DM.
The authors reported decrease in HbA1c of 1.63 % in the
pioglitazone group compared to 1.15 % in the sitagliptin
group. The average value of HbA1c at the end of the study
was the lowest in the pioglitazone group−6.84 % for pioglit-
azone and 7.32 % to sitagliptin. The data was statistically
significant and showed the notably greater effect of TZDs
on the glycemic profile of patients. When FPG reduction
was taken into account pioglitazone proved to be more ef-
ficient:−2.6 mmol/L for pioglitazone;−1.1 mmol/L for sita-
gliptin. Both drugs had a similar effect on the function of
β-cells, but pioglitazone significantly improved insulin
sensitivity compared to sitagliptin as measured by geomet-
ric mean HOMA-S (ratio of end point [last observation
carried forward] to baseline): [+1.5 (0,06)] for pioglitazone
and [+1.0 (0,04)] for sitagliptin.
Rosenstock et al. compared monotherapy with pioglit-
azone and monotherapy with vildagliptin and reported
significantly greater effectiveness for pioglitazone. It re-
duced HbA1c (1.4 ± 0.1 % reduction for monotherapy
with pioglitazone versus 1.1 ± 0.1 % for vildagliptin) and
FPG (1.9 ± 0.2 mmol/L reduction for pioglitazone versus
1.3 ± 0.2 mmol/L for vildagliptin) to a greater extent
than the gliptins [19].Pérez-Monteverde et al. reported results from a ran-
domized double-blind trial comparing the efficacy of sita-
gliptin and pioglitazone monotherapy. Reductions in
HbA1c were similar in both groups -−1.0 % and−0.9 % for
sitagliptin and pioglitazone, respectively. Both therapies
reduced FPG similarly:−1.48 mmol/L and−1.56 mmol/L
for sitagliptin and pioglitazone, respectively. It should be
noted that while sitagliptin was given in its maximum rec-
ommended dose of 100 mg from the very beginning, pio-
glitazone was not - patients received 15 mg which were
only later titrated to 30 mg [20] (Table 2).
Reported data has indicated that the probability of
reaching target HbA1c < 7 % is higher in the case of ther-
apy with pioglitazone [21].
The efficacy of combination therapy pioglitazone +
metformin as compared to the combination therapies
sitagliptin +metformin and vildagliptin +metformin
Few therapeutic agents for the treatment of T2DM address
both insulin resistance and β-cell function when adminis-
tered as monotherapy. Pioglitazone and metformin increase
insulin sensitivity and improve β-cell function, with TZDs
having a more prominent effect on β-cells. These character-
istics of the two drugs make their combination suitable
either as initial therapy, or as very rapid add-on therapy for
patients who do not achieve target glycemic control [22].
At the same time, gliptins (sitagliptin, vildagliptin) do not
influence insulin resistance [23]. In preclinical studies,
DPP-4 inhibitors have been shown to promote β-cell prolif-
eration but there is no clinical evidence yet of the protective
effects of incretin enhancers on β-cells in humans [24].
When comparing the combined therapy with pioglita-
zone and metformin with a combination of sitagliptin and
metformin, a number of studies have demonstrated the
advantage of combining the hypoglycaemic effects of met-
formin with those of TZDs (Table 2). Chawla et al. re-
ported changes in levels of HbA1c from baseline for
sitagliptin (group 1)−0.656 ± 0.21 % and−0.748 ± 0.35 %
for pioglitazone (group 2). After 16 weeks, the mean re-
ductions in FPG were 1.09 mmol/L and 1.69 mmol/L, re-
spectively, for group 1 and 2 [25]. In a randomized open-
label study, Liu et al. observed mean change in HbA1c
from baseline−0.94 ± 0.12 % with pioglitazone and−0.71 ±
0.12 % with sitagliptin, which again confirmed the positive
effect of TZDs. The mean change in FPG were−1.98 ±
0.22 mmol/L with pioglitazone and−1.27 ± 0.22 mmol/L
with sitagliptin, with a difference between the two groups
of−0.72 ± 0.32 mmol/L (P = 0.02) [26]. Bergenstal et al.
compared the glycemic effect of pioglitazone and sita-
gliptin as adjunctive therapy to metformin in patients
with T2DM in the study DURATION-2. Both therap-
ies led to reduced levels of HbA1c, but it was more
pronounced in the combination of pioglitazone and
metformin: sitagliptin (−0.9 %, 95 % CI−1.1 to−0.7)
Table 2 Comparative table of clinical trials investigating the efficacy of therapies based on glitazones versus gliptins



















246 MET 2000 mg −1.48 −2.0
163 PIO 45 mg −1.63 −2.6 p < 0.001
163 SIT 100 mg −1.15 −1.1
Rosenstock et al., 2007 [19] 161 PIO 30 mg 8.7 ± 1.0 −1.4 ± 0.1 −1.9 ± 0.2 SS
154 VIL 100 mg 8.6 ± 1.0 −1.1 ± 0.1 −1.3 ± 0.2
144 PIO + VIL 15/50 mg 8.8 ± 0.9 −1.7 ± 0.1 −2.4 ± 0.2 p < 0.001
148 PIO + VIL 30/100 mg 8.8 ± 0.9 −1.9 ± 0.1 −2.8 ± 0.2
Chawla et al., 2013 [25] 52 SIT + MET 100/>1500 mg 8.076 ± 0.722 −0.656 ± 0.21 −1.1 NS P = 0.268 for the
between group
differencePIO +MET 30/>1500 mg 8.228 ± 0.822 −0.748 ± 0.35 −1.7
Liu et al., 2013 [26] 60 SIT + MET + SU 100/≥1500/
half maximal dose
−0.71 ± 0.12 −1.27 ± 0.22 NS p = 0.16 between
group difference
for HbA1c59 PIO +MET + SU 30/≥1500/
half maximal dose
−0.94 ± 0.12 −1.98 ± 0.22
Bergenstal et al., 2010 [27] 170 EQW 2 mg +MET 8.5 −1.5 SS p < 0.0001 for
EQW vs. SIT; p = 0.0165
for EQW vs. PIO172 PIO 45 mg +MET −1.2
172 SIT 100 mg +MET −0.9
Lee et al., 2013 [28] 31 MET + gliclazide or
glimepiride
8.9 −2.5 From 9.24 to 5.71 SS p < 0.001 for difference
in HbA1cfrom baseline
for all groups
30 MET + PIO 15 mg 8.8 −2.8 From 9.66 to 6.16
38 MET + SIT 100 mg 9.4 −2.7 From 9.60 to 5.86
Blonde et al., 2009 [29] 1653 MET + VIL ≥1000/100 mg −0.68 ± 0.02 SS
825 MET + TZDs ≥1000 mg −0.57 ± 0.03 p = 0.001
Bolli et al., 2008, 2009
[30, 31]
295 MET + VIL > 1500/100 mg 8.4 ± 1.0 −0.88 ± 0.5 −1.4 ± 0.1 SS
p < 0.001 for all treatment
groups at week 52 vs. baseline
281 MET + PIO > 1500/30 mg 8.4 ± 0.9 −0.98 ± 0.06 −2.1 ± 0.1
Kaur M. et al., 2014 [32] 30 MET + VIL 500/50 mg 8.43 ± 0.75 −0.75 −1.75 SS
p < 0.001 for all treatment
groups vs. baseline
30 MET + PIO 500/15 mg 8.55 ± 0.84 −0.85 −1.85















Table 2 Comparative table of clinical trials investigating the efficacy of therapies based on glitazones versus gliptins (Continued)
Jindal et al., 2015 [1] 30 MET + PIO 1000/30 mg No values, the authors
comment that there are
not statistically
significant differences in
the reduction of HbA1c
between the two groups









p < 0.001 for all treatment
groups vs. baseline
30 MET + VIL 1000/100 mg
Kaur K. et al., 2014 [33] 25 PIO 30 mg +MET + SU 10.93 ± 2.9 −1.65 −2.83 SS
p < 0.001 for all
treatment
groups vs. baseline
25 VIL 50 mg +MET + SU 11.3 ± 0.6 −1.23 −3.35
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Lee et al. have concluded that dual therapies using com-
binations of metformin and pioglitazone or sitagliptin
show similar glycemic efficacy among patients with T2DM
[28]. The percentage of reduction in HbA1c, observed by
the authors has confirmed this statement (−2.8 % for pio-
glitazone with metformin;−2.7 % for sitagliptin with met-
formin), but it should be noted that while sitagliptin was
taken at the maximum recommended dose of 100 mg, pi-
oglitazone was not - patients received 15 mg while the
maximum recommended dose is 45 mg.
The randomized, open-label, comparative study GALI-
ANT, which assessed the effectiveness of treatment with
vildagliptin compared to TZDs as adjunctive therapy to
metformin (≥1000 mg/day) in patients with T2DM,
showed that changes in HbA1c levels in the two groups
did not differ significantly. The authors concluded that the
efficacy of both combination therapies is similar [29]. At
the same time Bolli et al. found that pioglitazone in
addition to metformin, is superior to vildagliptin + metfor-
min, as it leads to significant reductions in HbA1c (−0.98 ±
0.06 %) and FPG (−2.1 ± 0.1 mmol/L). In comparison, the
values obtained for these parameters in the group treated
with vildagliptin were−0.88 ± 0.5 % and−1.4 ± 0.1 mmol/L,
respectively [30, 31]. The objective of a prospective, open,
randomized, parallel study involving 90 patients was to de-
termine the effectiveness and safety of three combinations
of antihyperglycemic agents – metformin + pioglitazone;
vildagliptin + metformin; vildagliptin + pioglitazone. After
12 weeks of therapy, HbA1c fell by 0.85 % for metformin +
pioglitazone and by 0.75 % for vildagliptin + metformin. A
greater reduction of FPG was also reported in the group
treated with pioglitazone. Significant reduction of insulin
resistance was observed in all three groups, but when com-
paring metformin + pioglitazone and vildagliptin + metfor-
min, the advantage was again in favor of the TZDs - 28.75
% against 18.76 % for the gliptins [32]. A recent (2015) mul-
ticenter, open label, randomized, parallel study comparing
the effectiveness of vildagliptin and pioglitazone in combin-
ation with metformin, has shown that both drugs have
similar efficacy in improving glycemic control in patients
with T2DM for 24 weeks. There is a significant decrease in
FPG in both groups. There are no statistically significant
differences in the reduced levels of HbA1c after 12 and 24
weeks between the two groups. Improvements in glycemic
control influence favorably β-cell function in both groups
[1]. When comparing triple therapies with metformin, sul-
phonylurea and pioglitazone or vildagliptin, Kaur et al. re-
ported a significant decrease in HbA1c in the TZDs
group:−1.65 % in the comparison with−1.23 % for vilda-
gliptin [33].
Results have indicated that the combination therapy with
pioglitazone +metformin is more effective than sitagliptin
+metformin, while the comparison with vildagliptin +metformin has shown that the two treatment regimens
have similar efficacy.Safety of pioglitazone
T2DM is serious, chronic, progressive and widespread
disease. In patients with T2DM, the risk of macrovascu-
lar complications (coronary artery disease, peripheral ar-
terial disease, stroke) and microvascular complications
(diabetic nephropathy, neuropathy and retinopathy) is
high. In most of these patients metabolic disorders are
observed, which themselves are significant risk factors. It
is believed that the increased risk of cardiovascular com-
plications is due to not only but also to lipid disorders,
hypertension, chronic vascular inflammation and overall
state of susceptibility to atherothrombosis in patients
with diabetes. Patients with T2DM have an increased
risk of fragility fractures despite increased body weight
and normal or higher bone mineral density.
It is known that the efficiency of pioglitazone is associ-
ated with the implementation of good glycemic control and
improvement of insulin sensitivity on the one hand; on the
other hand it improves dyslipidemia, hypertension and
microalbuminuria in patients with T2DM. Some studies
have shown that pioglitazone increases the levels of HDL
cholesterol and reduces the levels of triglyceride, fasting
plasma free fatty acids, without affecting the levels of total
cholesterol and LDL cholesterol [34, 35]. As specific ago-
nists of the PPAR-γ, TZDs reduce the levels of circulating
pro-inflammatory biomarkers of atherosclerosis [36], more-
over, in patients treated with pioglitazone significantly lower
rate of progression of coronary atherosclerosis was ob-
served [37]. The effect of TZDs was associated with in-
creased levels of adiponectin (vascular protective
adipokine) and reduced levels of tissue necrosis factor α,
which in turn leads to a decreased risk of cardiovascular
complications. TZDs exert beneficial effect on coronary
and peripheral vasodilation, with minimal improvement of
blood pressure. Small controlled studies, using surrogate
markers such as the intima-media thickness of the carotid
artery, have shown improvements in patients treated with
TZDs [38]. Protective effect against restenosis after percu-
taneous intervention in TZDs treated patients was also in-
dicated [39, 40]. During the Duration-4 trial significant
changes in serum lipids were not observed. The decrease
in systolic blood pressure were:−1.3 mmHg (0.8
mmHg),−1.7 mmHg (1.0 mmHg), and−1.8 mmHg (1.0
mmHg) in therapy with exenatide, pioglitazone and sita-
gliptin, respectively. Reduction in diastolic blood pressure
is achieved only on therapy with pioglitazone:−2.5 mmHg
(0.6 mmHg). Compared with other drugs pioglitazone de-
creased heart rate [18].
ACT NOW study (for the prevention of diabetes) shows
that pioglitazone leads to a reduction of the risk of
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glycemic control in these patients [41].
In contrast to the aforementioned benefits, the TZDs, in
particular pioglitazone increased body weight (Table 3)
[1, 18, 19, 25, 31], in part because of differentiation of
adipocytes and expansion of adipocyte mass. Activation of
PPAR-γ stimulates differentiation to insulin-sensitive
smaller adipocytes and redistributes fat from visceral to
subcutaneous depots, a pattern that has been associated
with lower cardiovascular disease (CVD) risk. On the other
hand, DPP-4 inhibitors have generally neutral effect on
weight [1, 23, 31]. It was found out that there was no
weight gain with any DPP-4 inhibitors [SAXA: 0.06
(95 % CI−0.45, 0.57) SIT: 0.21 (95 % CI−0.1, 0.53)
VIL: 0.04 (95 % CI−0.37, 0.44)], but TZDs were asso-
ciated with significant increases in body weight [PIO:
2.06 (95 % CI 1.31, 2.81)] in a recent random-effects
network meta-analysis, which included 62 randomized
clinical trials (n = 32 185 participants) [42].
New or worsening peripheral edema is common
with TZD use, ranging from 2.5 % to 16.2 % inci-
dence, with risk increasing with age, increasing drug dose,
female sex, declining renal function, and concomitant in-
sulin use [39, 40]. Typical, but manageable, increases in
oedema (26.4 % vs 15.1 % for placebo) and weight gain
(mean change of +3.8 kg vs−0.6 kg for placebo) associated
with pioglitazone therapy in PROactive were reviewed by
Dormandy et al. [43].
Current drug labels for TZDs warn of increased
fractures, predominantly for distal fractures in women
[44–46]. A higher rate of bone fractures was observed
among pioglitazone-treated female patients (5.1 % vs
2.5 %) in PROactive study population [43]. Moreover,
a randomized, placebo-controlled trial demonstrated
that pioglitazone treatment was followed by decreased
lumbar and hip bone mineral density (BMD) and de-
creased measures of bone turnover in premenopausal
patients with polycystic ovary syndrome [47]. The
findings of a large, population-based, nested, case–control
analysis have provided further evidence that current use of
rosiglitazone and pioglitazone in women and men with
T2DM may be associated with an approximately 2- to 3-
fold increased risk of hip and nonvertebral osteoporotic
fractures [48]. Colhoun et al. observed hip fractures in both
sexes and the risk was similar for pioglitazone users and
rosiglitazone users [49]. Furthermore, not all studies have
demonstrated such an increase in risk. According to Baze-
lier et al., risk of osteoporotic fracture was similar for TZD
users and insulin users, but versus nondiabetic patients
TZD users showed a 1.3-fold increased risk of fracture. In
their opinion the underlying T2DM should be taken into
account, when studying fracture risk with TZDs [46]. The
results of a prospective, double-blind study did not demon-
strate a causal relationship between pioglitazone treatmentfor 12 months and loss of bone mass or alteration of bone
remodeling that would be expected to result in excessive
bone fragility [50]. The effect of TZDs on bone is a drug
class effect and duration of treatment is proportional with
increased fracture risk [51]. Preclinical studies have sug-
gested that incretin-based therapies may be beneficial for
the bone; however, clinical data are largely lacking. A meta
analysis performed by Monami et al. on all trials that en-
rolled T2DM patients that received DPP-4 inhibitors for at
least 24 weeks suggested that DPP-4 inhibitors could be as-
sociated with reduced risk of bone fracture [52], but the
duration of included trials was short and bone fracture were
not the principal end points in any of the studies and were
reported only as adverse events, and were probably not de-
scribed carefully. A neutral role of DPP-4 inhibitors on
bone metabolism was demonstrated by treatment with vil-
dagliptin (100 mg once daily) in drug naïve type 2 diabetic
patients for 1 year. Circulating levels of markers of bone
resorption (cross-linked C-terminal telopeptide) and
calcium homeostasis (serum alkaline phosphatase,
calcium, and phosphate) were unaffected compared to
baseline and to placebo [53]. However, clinical evidence
for DPP-4 inhibitors in humans is still not enough to allow
definitive conclusions and further studies are required for
their long-term efficacy and safety on bone metabolism.
Pioglitazone carries black box label warnings about
its potential to cause or exacerbate congestive heart
failure and is contraindicated in patients with New
York Heart Association class III or IV heart failure
(HF) [54]. Pioglitazone is the only hypoglycemic drug,
other than metformin, with conducted randomized trial
which has clearly demonstrated that it reduces mortal-
ity, myocardial infarction and stroke. PROactive is a
large, prospective, randomized, double-blind study that
examined the effect of pioglitazone (45 mg
/day) on macrovascular complications in 5238 patients
with T2DM and concomitant cardiovascular diseases.
The study showed that pioglitazone non-significantly
reduces (10 %) the risk of the composite primary end-
point— death from any cause, non-fatal myocardial in-
farction (including silent myocardial infarction), stroke,
acute coronary syndrome, leg amputation, coronary
revascularisation, or revascularisation of the leg. The
pre-defined main secondary endpoint—all-cause mortality,
myocardial infarction, or stroke—was also significantly re-
duced, in the pioglitazone group. Despite the increase in re-
ported heart failure in the pioglitazone group, the number
of deaths from heart failure was similar in each group [55].
Pioglitazone is beneficial in reducing the chances of a
patient who has had a stroke from having further stroke.
A subgroup analysis from PROactive study found that pio-
glitazone reduced the occurrence of fatal or non-fatal
stroke (5.6 % in the pioglitazone group against 10.2 % in
the placebo group) and mortality due to cardiovascular
Table 3 Comparative table of clinical trials and studies, investigating the safety of treatment with gliptins and glitazones
Author Treatment Change in mean body weight
Bolli et al., 2009 [31] VIL + MET ↑ 0.2 kg, non-significant
PIO +MET ↑ 2.6 kg, P < 0.001
Jindal et al., 2015 [1] VIL + MET No change in body weight
PIO +MET ↑1.2 ± 0.5 kg
Chawla et al., 2013 [25] SIT + MET ↓ 0.58 kg, statistically significant
PIO +MET ↑0.90 kg, statistically significant
Russell-Jones et al., 2012 [18] EQW ↓ 2.0 kg
MET ↓ 2.0 kg (P = 0.892 vs. EQW)
PIO ↑ 1.5 kg (P < 0.001 vs. EQW)
SIT ↓ 0.8 kg (P < 0.001 vs. EQW)
Rosenstock et al., 2007 [19] VIL ↑ 0.2 ± 0.3 kg
PIO ↑ 1.5 ± 0.3 kg
VIL + PIO (50/15 mg) ↑ 1.4 ± 0.3 kg
↑ 2.1 ± 0.3 kgVIL + PIO (100/30 mg)
Risk of fractures
Bone et al., 2013 [50] PIO BMD of total proximal femur (primary and point):
PLB Least squares mean from baseline: −0.69 % PIO, −0.14 % PLB (P = 0.170)
statistically non-significant
Bone remodeling markers:
statistically non-significant between-group differences
Bazelier et al., 2012 [46] Biguanide or Sulfonyluerum ↓ risk HR = 1.15, 95 % CI 1.13–1.18
Biguanide and Sulfonyluerum ↓ risk HR = 1.00, 95 % CI 0.96–1.04
TZDs ↑ risk HR = 1.27, 95 % CI 1.06–1.52
Insulin ↑ risk HR = 1.25, 95 % CI 1.20–1.31
Glintborg et al., 2008 [47] PIO ↓BMD [geometric means (−2 to +2SD): lumbar spine 1.140 (0.964–1.348) vs.
1.127 (0.948–1.341)g/cm2 (average decline 1.1 %) and femoral neck 0.966
(0.767–1.217) vs. 0.952 (0.760–1.192)g/cm2 (average decline 1.4 %), both p < 0.05]PLB
Meier et al., 2008 [48] PIO ↑ hip and nonvertebral osteoporotic fractures OR = 2.59, 95 % CI 0.96–7.01
ROSI ↑ hip and nonvertebral osteoporotic fractures OR = 2.38, 95 % CI 1.39–4.09
Colhoun et al., 2012 [49] PIO ↑hip fractures risk OR = 1.18, 95 % CI 1.00–1.40
ROSI ↑hip fractures risk OR = 1.16, 95 % CI 1.06–1.26
Bunck et al., 2012 [53] VIL Bone resorption marker: S-CTx (cross-linked C-terminal telopeptide):
between-group ratio 1.15 ± 0.17, P = 0.320 serum alkaline phosphatase,
calcium and phosphate - unaffectedPLB
Monami et al., 2011 [52] DPP-4 ↑ risk of bone fractures Mantel Haenszel odds ratio [MH-OR] 0.60, 95 %
CI 0.37–0.99, P = 0.045
PLB, other
treatments
Risk of cardiovascular complications
Dormandy et al., 2005 [55] PIO ↓ all-cause mortality, non-fatal myocardial infarction, and stroke (main
secondary endpoint)
↑ HF (11 % vs. 8 %, p < 0.0001)
PLB
Wilcox et al., 2007 [56] PIO ↓ fatal or nonfatal stroke (HR = 0.53, 95 % CIs = 0.34–0.85; P = 0.0085)
↓ cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
(HR = 0.72, 95 % CIs = 0.53–1.00; P = 0.0467)
PLB
Nissen et al., 2007 [57] ROSI ↑ myocardial infarction (OR = 1.43, 95 % CI, 1.03–1.98; P = 0.03)
Filipova et al. Diabetology & Metabolic Syndrome  (2015) 7:63 Page 8 of 16
Table 3 Comparative table of clinical trials and studies, investigating the safety of treatment with gliptins and glitazones (Continued)
↑ death from cardiovascular causes (OR = 1.64, 95 % CI, 0.98–2.74; P = 0.06)
Control group
Lincoff et al., 2007 [59] PIO ↓ death, myocardial infarction, or stroke (OR = 1.43, 95 % CI, 1.03–1.98; P = 0.03)
↑ HF (НR, 1.41; 95 % CI, 1.14–1.76; P = 0.002)
Control group
Gallagher et al., 2011 [63] PIO
ROSI ↑ death (RR 1.20; 95 % CI 1.08–1.34)
↑ HF (RR 1.73; 95 % CI 1.19–2.51)
Breunig et al., 2014 [62] PIO
ROSI ↑ HF (HR = 1,79, 95 % CI = 1.16–2.76, P = 0.009)
MET
Seong et al., 2015 [61] PIO +MET ↓risk of CVD 0.89 (95 % CI, 0.81–0.99)
↓risk of IS 0.81 (95 % CI, 0.67–0.99)
↑risk of HF 4.81 (95 % CI, 3.53–6.56)
DPP-4i + MET
Scirica et al., 2013 [65] SAXA ↑ HF (HR 1.27; 95 % CI, 1.07–1.51; P = 0.007)
Scirica et al., 2014 [66] PLB
Monami et al., 2014 [67] DPP-4 inhibitors ↑ HF (MH-OR: 1.19[1.03; 1.37]; p = 0.015).
Control group
Clifton P, 2014 [68] DPP-4 inhibitors ↑ HF
Control group
Wang et al., 2014 [69] SIT ↑ HF (HR: 1.09, 95 % CI: 1.06–1.11, P < 0.001).
Control group
Chen et al., 2014 [70] SIT ↑ recurrent myocardial infarction (HR, 1.73; 95 % CI, 1.15–2.58; P = 0.008)
↑ percutaneous coronary revascularization (HR, 1.43; 95 % CI, 1.04–1.95; P = 0.026)
Control group
Effects on liver
Belfort et al., 2006 [72] PIO ↓alanine transaminase (by 58 % vs. 34 %, P < 0.001)
↑hepatic insulin sensitivity (by 48 % vs. 14 %, P = 0.008)
↓liver fat (by 54 % vs. 0 %, P < 0.001)
↓liver inflammation (P = 0.008)
↓ballooning necrosis (P = 0.02)
Fibrosis not improved (P = 0.08)
PLB
Aithal et al., 2008 [73] PIO ↓ hepatocellular injury (P = 0.005)
↓Mallory-Denk bodies (P = 0.004)
↓ alanine aminotransferase level (−10.9 vs −36.2 u/L; P = 0.009)
↓ gamma-glutamyltransferase level (−9.4 vs −41.2 u/L; P = 0.002)
↓ ferritin (−11.3 vs −90.5 μg/L; P = 0.01)
Fibrosis improved (P = 0.05)
PLB
Sanyal et al., 2010 [74] PIO ↓ serum alanine and aspartate aminotransferase levels (P < 0.001)
↓ insulin resistance (P = 0.03)
↓ liver inflammation (P = 0.004)
↓ ballooning necrosis (P = 0.08)
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Fibrosis not improved (P = 0.12)
PLB
Ohki et al., 2012 [77] SIT ↓ aspartate aminotransferase (P = 0.47)
↓ alanine aminotransaminase (P = 0.03)
↓ gamma-glutamyltransferase (P = 0.01)
PIO ↓ aspartate aminotransferase (P < 0.01)
↓ alanine aminotransaminase (P < 0.01)
↓ gamma-glutamyltransferase (P < 0.01)
Iwasaki et al., 2011 [75] SIT ↓ alanine transaminase, aspartate aminotransferase, gamma-glutamyltransferase
Itou et al., 2012 [76] SIT – case report ↓ alanine transaminase, aspartate aminotransferase
↓ insulin resistance
↓ liver fat
Risk of development of oncological disease
Azoulay et al., 2013 [2] PIO ↑ bladder cancer (RR 1.83, 95 % CI 1.10–3.05)
Wei et al., 2013 [87] PIO ↓ bladder cancer (HR, 1.16, 95 % CI 0.83, 1.62)
Active control
Govindarajan et al., 2007 [34] PIO ↓lung cancer (RR, 0.67; 95 % CI, 0.51–0.87)
Active control
Mazzone et al., 2012 [56] TZDs ↓ lung cancer (OR 0.86, 95 % CI 0.4–1.85, p = 0.14)
MET ↓ lung cancer (OR 0.48, 95 % CI 0.28–0.81, p = 0.006)
Nelson et al., 2014 [31] SIT - case report ↑ pancreatitis
Girgis and Champion, 2011 [81] VIL - case report ↑ acute pancreatitis
Singh et al., 2013 [27] EQW/SIT ↑acute pancreatitis (OR 2.01, 95 % CI [1.37–3.18], P = 0.01)
Engel et al., 2013 [45] SIT Comparator agent Rates of malignancy (−0.05 (95 % CI −0.41, 0.30)
Rate of category of pancreatic cancer (adenocarcinoma of pancreas, pancreatic
carcinoma, pancreatic carcinoma metastatic) (0.05 and 0.06 events per 100
patient-years in the sitagliptin and nonexposed groups, respectively)
ROSI rosiglitazone, SAXA saxagliptin, АLO alogliptin, BMD bone mineral density, CVD cardiovascular disease, IS ischemic stroke
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stroke (13.0 % in the pioglitazone group against 17.7 % in
the placebo group) compared with placebo [56].
Whilst a meta-analysis has raised concerns regarding
the possibility of cardiovascular complications associated
with rosiglitazone [57, 58], another meta-analysis of pio-
glitazone trials showed that among the diverse population
of patients with T2DM, treatment with pioglitazone was
associated with a significant decrease in risk of myocardial
infarction, stroke or death [59, 60]. The results of a
population-based cohort study showed that pioglitazone +
metformin was associated with decreased risks of total
cardiovascular disease and ischemic stroke compared with
DPP-4 inhibitor + metformin. However, the risk of HF
was higher in patients receiving pioglitazone + metformin
[61]. Compared with metformin the risk of developing HF
in Medicaid (US government insurance program) patients
was higher in patients started on rosiglitazone, but not pi-
oglitazone [62]. The study, which supported the suspen-
sion of rosiglitazone by European regulatory authorities inSeptember 2010, determined that current rosiglitazone
users had an increased risk of death (adjusted RR 1.20; 95
% CI 1.08–1.34) and hospitalization for HF (adjusted RR
1.73; 95 % CI 1.19–2.51) compared to current pioglitazone
users [63]. The difference between rosiglitazone and pio-
glitazone in regard to cardiovascular complications sug-
gests that these effects are rather associated with the TZD
type, but are not a drug class effect. It was found that pio-
glitazone is associated with greater PPAR-γ activation than
rosiglitazone [64]. A retrospective review showed that
treatment with pioglitazone was associated with greater
beneficial effects on blood lipid levels (triglycerides, total
cholesterol, and LDL-C) than rosiglitazone [34]. There-
fore, differential therapeutic modulation of lipid levels
might confer a different level of protection from cardio-
vascular disease in patients with T2DM.
T2DM and HF often coexist, and together, these con-
ditions are associated with increased morbidity and
mortality compared with each of them individually. The
cardiovascular safety and efficacy of pioglitazone is
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4. Recently (2013), cardiovascular safety and efficacy of
saxagliptin was estimated in 16 492 patients with
T2DM and concomitant cardiovascular risk factors in
the study - Saxagliptin Assessment of Vascular Out-
comes Recorded in Patients With Diabetes Mellitus
(SAVOR) - Thrombolysis in Myocardial infarction
(TIMI) 53. Scirica et al. analyzed in detail the risk of
occurrence of HF in this study. It was found that more
patients in the saxagliptin group are hospitalized due to
HF (3.5 % vs. 2.8 %; HR, 1.27; 95 % CI, 1.07 to 1.51;
P = 0.007) and this DPP-4 inhibitor did not provide
any cardioprotective benefit [65, 66]. In a meta-analysis
that included 84 studies it was established that the overall
risk of HF was higher in patients treated with DPP-4 in-
hibitors compared with placebo/active control without
any clear evidence of differences among drugs of the class
[67]. Data from another meta-analysis revealed that in the
randomized, controlled trials (including sitagliptin, saxa-
gliptin and alogliptin) the risk of HF in patients using
DPP-4 inhibitors was 24 % [68].
The available evidence suggests that the DPP-4 inhibitors
are associated with increased risk of HF [67–69] as well as
they have unproven safety with respect to the cardiovascu-
lar system. Patients with T2DM, chronic kidney disease and
acute myocardial infarction were included in a cohort study
which demonstrated that using sitagliptin increased the risk
of recurrent myocardial infarction and percutaneous coron-
ary revascularization [70].
In 2008 the Food and Drug Administration (FDA) in
the United States required that the cardiovascular
safety for all glucose lowering drugs was proven, and
this began to be applied to new antidiabetic drugs:
DPP-4 inhibitors. In 2013–2014 many studies with DPP-4
inhibitors were conducted, which have definitely shown a
higher risk of developing HF and the cardiovascular safety
of these inhibitors has to be demonstrated. On the other
hand, the benefits and safety of pioglitazone on the cardio-





PIO 30 1.56156 (0.79841)
SIT 100 2.64929 (1.35456)
VIL 100 2.73429 (1.39802)
PIO +МET 15/850 mg 30/2000 1.68522 (0.86164)
PIO +МET 15/1000 mg 30/2000 1.68522 (0.86164)
SIT + MET 50/850 mg 100/2000 3.18204 (1.62695)
SIT + MET 50/1000 mg 100/2000 3.20408 (1.63822)
VIL +МET 50/850 mg 100/2000 3.24533 (1.65931)
VIL + MET 50/1000 mg 100/2000 3.08333 (1.57407)marketing trials of DPP-4 inhibitors have shown that these
drugs neither reduce nor increase the risk of major cardio-
vascular events compared with placebo [65, 71]. The safety
of gliptins regarding the cardiovascular system has not been
established in the long term.
Another advantage of pioglitazone, which character-
izes its safe and efficient profile is its effect on liver
histology, and hence its use for treatment of non-
alcoholic fatty liver disease. Several studies have shown
that the use of pioglitazone leads to reduced levels of
liver enzymes and inflammatory markers of necrosis
and improvements of fibrosis, steatosis and insulin sen-
sitivity [72–74]. Several clinical studies with sitagliptin
in subjects with T2DM and nonalcoholic steatohepatitis
have shown decreases in alanine aminotransferase
levels and improved liver histology [75–77]. Clinical
data for the DPP-4 inhibitors is very scarce and the in-
formation is derived from non-randomized studies con-
ducted in small groups of patients; this is why it is
difficult to make final conclusions [78, 79].
Definitive data in humans, associating the TZDs with
cancer development is not available. Azoulay et al., re-
ported an increased risk of bladder cancer in the group of
patients using pioglitazone (HR 1.83; 95 % CI 1.10–3.05)
[80], while Wei et al., analyzed the risk in 23,548 patients
exposed to pioglitazone and 184,166 exposed to other an-
tidiabetic treatments and reported that pioglitazone may
not be significantly associated with an increased risk of
bladder cancer (1.16; 95 % CI 0.83–1.62) [81, 82]. The lar-
gest study examining the side effects of pioglitazone -
PROactive detected more cases of bladder cancer in the
pioglitazone group, although the difference was not statis-
tically significant. But in the same trial statistically signifi-
cant reduction of cases with breast cancer in the
pioglitazone group was observed. Other studies have dem-
onstrated the protective effect of TZDs against the develop-
ment of lung cancer in patients with diabetes [83, 84]. The
Agency’s Committee for Medicinal Products for Human
Use (CHMP) concluded that, although there is a small riskCost of monthly therapy, Relative difference in the










Table 5 Effectiveness of annual costs during treatment with pioglitazone (monotherapy and combination therapy) in Bulgaria
Treatment Number of packs
sold in 2014
Expenses, BGN (EUR) Number of patients
taking DDD
Cost of therapy with PIO
or PIO +MET, BGN (EUR)
Difference, BGN (EUR) Amount reimbursed by
the NHIF, BGN (EUR)
SIT 25,072 1,859,840.96 (950,921.58) 25,072 1,177,623.20 (602,109.18) 682,217.76 (348,812.40) 682,217.76 (348,812.40)
VIL 6,088 233,048.64 (119,155.88) 3,044 142,611.40 (72,916.05) 90,437.24 (46,239.83) 90,437.24 (46,239.83)
SIT + MET 50/850 mg 141,986 6,325,476.30 (3,234,164.68) 70,993 3,588,696.15 (1,834,871.21) 2,736,780.15 (1,399,293.47) 1,368,390.07 (699,646.73)
SIT + MET 50/1000 mg 257,550 11,553,693.00 (5,907,309.43) 128,775 6,508,288.50 (3,327,634.81) 5,045,404.50 (2,579,674.36) 2,522,702.25 (1,289,837.18)
VIL + MET 50/850 mg 53,980 5,255,492.80 (2,687,090.80) 26,990 1,364,344.50 (697,578.27) 3,891,148.30 (1,989,512.53) 1,945,574.15 (994,756.27)
VIL + MET 50/1000 mg 128,665 11,901,512.50 (6,085,146.72) 64,332.5 3,251,364.55 (1,662,396.30) 8,650,147.95 (4,422,750.42) 4,325,074.98 (2,211,375.72)
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outweigh its risks in a limited population of type 2 diabetes
patients (www.ema.europa.eu - Accessed on 21/7/201). On
the other hand, data from studies, warnings of the
European Medicines Agency (EMA) and the FDA
have shown that there is increased risk of developing
acute pancreatitis and pancreatic cancer in therapy
with incretin-based agents: exenatide, liraglutide, sita-
gliptin, saxagliptin, vildagliptin, alogliptin and linaglip-
tin. A lot of conflicting data [85–89] concerning the
serious side effects of incretin-based therapies is cur-
rently available and published each month. Neverthe-
less, the widespread use of these drugs, the evaluation
of short- and long-term risks should be considered as
a priority [90].
Based on these facts, the balance between benefits
and risks supports the use of pioglitazone to reduce the
morbidity and mortality associated with T2DM.
Costs comparison
In order to determine the benefits in terms of costs, the
defined daily dose, the monthly cost of the treatment
course and the level of reimbursement by the National
Health Insurance Fund (NHIF) should be taken into ac-
count. The defined daily dose (DDD) for pioglitazone is
30 mg, and for sitagliptin and vildagliptin – 100 mg. Ac-
cording to the updated PDL the reimbursement rate for
pioglitazone is 25 %. In comparison, sitagliptin and vilda-
gliptin are reimbursed at 100 % by NHIF, despite their
much higher wholesale price. Table 4 provides the refer-
ence prices of mono and combination therapies with the
three antihyperglycemic drugs. All prices are given in
BGN and EUR with current exchange rates of 1.95583
BGN for 1 EUR according to Bulgarian National Bank.
Given that the effectiveness of pioglitazone is compar-
able or even better than that of gliptins and it has shown
better safety than them, then the exchange of mono- and
combination therapy with gliptins with monotherapy and
combination therapy with pioglitazone will allow savings
of public funds to be realized by NHIF.
Data on the amount of sold packs of sitagliptin, vildaglip-
tin and their combination with metformin has been taken
from IMS Health database. It was estimated that if sitaglip-
tin or vildagliptin monotherapy was exchanged with pioglit-
azone monotherapy and it was reimbursed by 100 %
682,217.76 BGN (348,812.40 EUR) and 90,437.24 BGN
(46,239.83 EUR) will be saved, respectively (Table 5).
Therefore, if therapies with sitagliptin + metformin and
vildagliptin + metformin are replaced with pioglitazone +
metformin and reimbursed at 50 %, the NHIF would realize
savings for BGN 10,161,740.45 (5,195,615.39 EUR).
Our results are confirmed by Klarenbach et al., who used
the United Kingdom Prospective Diabetes Study Outcomes
Model to predict diabetes-related complications, quality-adjusted life-years (QALY) and costs of alternative second-
line therapies available in Canada for adults with T2DM in-
adequately controlled by metformin. DPP-4 inhibitors,
basal insulin and biphasic insulin are more costly and lead
to fewer QALYs than TZDs, they are dominated by the
TZDs (which are less expensive and more effective) [91].
An economic modeling analysis carried out in the
USA suggested that pioglitazone may deliver superior
economic value when compared to sitagliptin due to im-
proved HbA1c and cardiovascular outcomes at reason-
able incremental cost [92].Conclusion
Pioglitazone has a glycemic profile which is superior or
similar to that of newer antidiabetic drugs (DPP-4 inhibi-
tors). It does not increase the risk of cardiovascular compli-
cations and has a manageable safety profile. At present the
commonly used therapies with newer drugs (sitagliptin and
vildagliptin) seem to be both less effective and less safe. Fur-
thermore, none affect insulin sensitivity as beneficially as
pioglitazone. In addition to its favorable effect on glycemic
parameters pioglitazone proves to be cost-effective when
compared to sitagliptin and vildagliptin. Nevertheless, glip-
tins have a growing market share, despite the lack of
data on long-term safety and their higher price. If the drug
and reimbursement policy in Bulgaria follows the princi-
ples for reimbursement of cost-effective treatments and
gives preference to pioglitazone, it could save up to BGN
10,934,395.45 (5,590,649.35 EUR).
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